KIT and PDGFRA mutations in gastrointestinal stromal tumors (GISTs)

Seminars in Diagnostic Pathology

Volumn 23, Issue 2, 2006, Pages 91-102

  Lasota, Jerzy ^a   Miettinen, Markku ^a  

^a ARMED FORCES INSTITUTE OF PATHOLOGY   (United States)

Author keywords

Deletion; Duplication; Gastrointestinal stromal tumors; KIT; Missense mutation; Mutation; PDGFRA

Indexed keywords

ASPARTIC ACID; IMATINIB; PHOSPHOTRANSFERASE; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; STEM CELL FACTOR; SUNITINIB; VALINE;

ARTICLE; CANCER RESISTANCE; CODON; DRUG RESISTANCE; DRUG SENSITIVITY; EPITHELIOID CELL; EXON; FAMILIAL DISEASE; GASTROINTESTINAL STROMAL TUMOR; GENE CLUSTER; GENE DELETION; GENE DUPLICATION; GENE FREQUENCY; GENE MUTATION; GENETIC RESISTANCE; GENOTYPE; HUMAN; INTESTINE TUMOR; MUTATION RATE; MUTATIONAL ANALYSIS; NEUROFIBROMATOSIS; NONHUMAN; NUCLEOTIDE SEQUENCE; ONCOGENE; PATHOGENESIS; POINT MUTATION; PRIORITY JOURNAL; PROTEIN DOMAIN; RECEPTOR UPREGULATION; SOMATIC MUTATION; STOMACH TUMOR;

ADOLESCENT; AMINO ACID SEQUENCE; ANTINEOPLASTIC AGENTS; BASE SEQUENCE; CHILD; GASTROINTESTINAL STROMAL TUMORS; HUMANS; MOLECULAR CONFORMATION; MOLECULAR SEQUENCE DATA; MUTATION; NEUROFIBROMATOSIS 1; PIPERAZINES; PROGNOSIS; PROTEIN STRUCTURE, TERTIARY; PROTO-ONCOGENE PROTEINS C-KIT; PYRIMIDINES; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA;

EID: 33750623679     PISSN: 07402570     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.semdp.2006.08.006     Document Type: Article

References (147)

1. Besmer P., Murphy J.E., George P.C., et al. A new acute transforming feline retrovirus and relationship of its oncogene v-kit with the protein kinase gene family. Nature 320 (1986) 415-421
2. Matsui T., Heidaran M., Miki T., et al. Isolation a novel receptor cDNA establishes the existence of two PDGF receptor genes. Science 243 (1989) 800-804
3. Roberts W.M., Look A.T., Ruossel M.F., et al. Tandem linkage of human CSF-1 receptor (c-fms) and PDGF receptor genes. Cell 55 (1989) 655-661
4. Stenman G., Eriksson A., and Claesson-Welsh L. Human PDGFA receptor gene maps to the same region on chromosome 4 as the KIT oncogene. Genes Chromosomes Cancer 1 (1989) 155-158
5. Pawson T. Regulation and targets of receptor tyrosine kinases. Eur J Cancer 38 (2002) S3-S10
6. Fletcher J.A. Role of KIT and platelet-derived growth factor receptors as oncoproteins. Semin Oncol 31 suppl 6 (2004) 4-11
7. Yarden Y., Kuang W.J., Yang Feng T., et al. Human proto-oncogene c-kit: a new cell surface receptor tyrosine kinase for an unidentified ligand. EMBO J 6 (1987) 3341-3351
8. Chabot B., Stephenson D.A., Chapman V.M., et al. The protooncogene c-kit encoding a transmembrane tyrosine kinase receptor maps to the mouse W locus. Nature 335 (1988) 88-89
9. Williams D.E., Eisenman J., Baird A., et al. Identification of a ligand for the c-kit protooncogene. Cell 63 (1990) 167-174
10. Zsebo K.M., Williams D.A., Geissler E.N., et al. Stem cell factor is encoded at the S1 locus of the mouse and is the ligand for the c-kit tyrosine kinase receptor. Cell 63 (1990) 213-224
11. Blume-Jensen P., Claesson-Welsh L., Siegbahn A., et al. Activation of the human c-kit product by ligand-induced dimerization mediates circular actin reorganization and chemotaxis. EMBO J 10 (1991) 4121-4128
12. Maeda H., Yamagata A., Nishikawa S., et al. Requirement of c-kit for development of intestinal pacemaker system. Development 116 (1992) 369-375
13. Lev S., Blechman J., Nishikawa S., et al. Interspecies molecular chimeras of kit helps define the binding site of the stem cell factor. Mol Cell Biol 13 (1993) 2224-2234
14. Huizinga J.D. Gastrointestinal peristalsis: joint action of enteric nerves, smooth muscle, and interstitial cells of Cajal. Microsc Res Tech 47 (1999) 239-247
15. Hirota S., Isozaki K., Moriyama Y., et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 279 (1998) 577-580
16. Heinrich M.C., Corless C.L., Duensing A., et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science 299 (2003) 708-710
17. Longley B.J., Reguera M.J., and Ma Y. Classes of c-KIT activating mutations: proposed mechanisms of action and implications in disease classification and therapy. Leuk Res 25 (2001) 571-576
18. Heinrich M.C., Rubin B.P., Longley B.J., et al. Biology and genetic aspects of gastrointestinal stromal tumors: KIT activation and cytogenetic alterations. Human Pathol 33 (2002) 484-495
19. London C.A., Galli S.J., Yuuki T., et al. Spontaneous canine mast cell tumors express tandem duplications in the proto-oncogene c-kit. Exp Hematol 27 (1999) 689-697
20. Ma Y., Longley B.J., Wang X., et al. Clustering of activating mutations in c-KIT's juxtamembrane coding region in canine mast cell neoplasms. J Invest Dermatol 112 (1999) 165-170
21. Nakahara M., Isozaki K., Hirota S., et al. A novel gain-of-function mutation of c-kit gene in gastrointestinal stromal tumors. Gastroenterology 115 (1998) 1090-1095
22. Nishida T., Hirota S., Taniguchi M., et al. Familial gastrointestinal stromal tumours with germline mutation of the KIT gene. Nat Genet 19 (1998) 323-324
23. Isozaki K., Terris B., Belghiti J., et al. Germline-activating mutation in the kinase domain on KIT gene in familial gastrointestinal stromal tumors. Am J Pathol 157 (2001) 1581-1585
24. Beghini A., Tibiletti M.G., Roversi G., et al. Germline mutation in the juxtamembrane domain of the kit gene in a family with gastrointestinal stromal tumors and urticaria pigmentosa. Cancer 92 (2001) 657-662
25. Maeyama H., Hidaka E., Ota H., et al. Familial gastrointestinal stromal tumor with hyperpigmentation: association with a germline mutation of the c-kit gene. Gastroenterology 120 (2001) 210-215
26. Hirota S., Nishida T., Isozaki K., et al. Familial gastrointestinal stromal tumors associated with dysphagia and novel type germline mutation of KIT gene. Gastroenterology 122 (2002) 1493-1499
27. Chompret A., Kannengiesser C., Barrois M., et al. PDGFRA germline mutation in a family with multiple cases of gastrointestinal stromal tumor. Gastroenterology 126 (2004) 318-321
28. Robson M.E., Glogowski E., Sommer G., et al. Pleomorphic characteristics of a germ-line KIT mutation in a large kindred with gastrointestinal stromal tumors, hyperpigmentation, and dysphagia. Clin Cancer Res 10 (2004) 1250-1254
29. Carballo M., Roig I., Aquilar F., et al. Novel c-KIT germline mutation in a family with gastrointestinal stromal tumors and coutaneous hyperpigmantation. Am J Med Genet A 132 (2005) 361-364
30. Li F.P., Fletcher J.A., Heinrich M.C., et al. Familial gastrointestinal stromal tumor syndrome: phenotypic and molecular features in a kindred. J Clin Oncol 23 (2005) 2735-2743
31. Tarn C., Merkel E., Canutescu A.A., et al. Analysis of KIT mutations in sporadic and familial gastrointestinal stromal tumors: therapeutic implications through protein modeling. Clin Cancer Res 11 (2005) 3668-3677
32. O'Riain C., Corless C.L., Heinrich M.C., et al. Gastrointestinal stromal tumors: insights fro a new familial GIST kindred with unusual genetic and pathologic features. Am J Surg Pathol 29 (2005) 1680-1683
33. Lasota J., and Miettinen M. A new familial GIST identified. Am J Surg Pathol 30 (2006) 1342
34. Sommer G., Agosti V., Ehlers I., et al. Gastrointestinal stromal tumors in a mouse model by targeted mutation of the Kit receptor tyrosine kinase. Proc Natl Acad Sci USA 100 (2003) 6706-6711
35. Rubin B.P., Antonescu C.R., Scott-Browne J.P., et al. A knock-in mouse model of gastrointestinal stromal tumor harboring Kit K641E. Cancer Res 65 (2005) 6631-6639
36. Chen H., Hirota S., Isozaki K., et al. Polyclonal nature of diffuse proliferation of interstitial cells of Cajal in patients with familial and multiple gastrointestinal stromal tumours. Gut 51 (2002) 793-796
37. Ogasawara N., Tsukamoto T., Inada K., et al. Frequent c-KIT gene mutations not only in gastrointestinal stromal tumors but also in interstitial cells of Cajal in surrounding normal tissue. Cancer Letter 230 (2005) 199-210
38. Hirota S., and Isozaki K. Pathology of gastrointestinal stromal tumors. Pathol Int 56 (2006) 1-9
39. Lux M.L., Rubin B.P., Biase T.L., et al. KIT extracellular and kinase domain mutations in gastrointestinal stromal tumors. Am J Pathol 156 (2000) 791-795
40. Lasota J., Wozniak A., Sarlomo-Rikala M., et al. Mutations in exons 9 and 13 of KIT gene are rare events in gastrointestinal stromal tumors. A study of two hundred cases. Am J Pathol 157 (2000) 1091-1095
41. Rubin B.P., Singer S., Tsao C., et al. KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Res 61 (2001) 8118-8121
42. Lasota J., Dansonka-Mieszkowska A., Sobin L.H., et al. A great majority of GISTs with PDGFRA mutations represents gastric tumors of low or no malignant potential. Lab Invest 84 (2004) 874-883
43. Corless C.L., Schroeder A., Griffith D., et al. PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib. J Clin Oncol 23 (2005) 5357-5364
44. Lasota J., Stachura J., and Miettinen M. GISTs with PDGFRA exon 14 mutations represent subset of clinically favorable gastric tumors with epithelioid morphology. Lab Invest 86 (2006) 94-100
45. Beghini A., Ripamonti C.B., Cairoli R., et al. KIT activating mutations: incidence in adult and pediatric acute myeloid leukemia, and identification of an internal tandem duplication. Haematologica 89 (2004) 920-925
46. Wang Y.Y., Zhou G.B., Yin T., et al. AML1-ETO and c-kit mutation/overexpression in t(8;21) leukemia: implication in stepwise leukemogenesis and response to Gleevec. Proc Natl Acad Sci USA 102 (2005) 1104-1109
47. Longley B.J., Tyrrell L., Lu S.-Z., et al. Somatic c-KIT activating mutation in urticaria pigmentosa and aggressive mastocytosis: establishement of clonality in a human mast cell neoplasm. Nat Genet 12 (1996) 312-314
48. Longley B.J., Metcalfe D.D., and Tharp M. Activating and dominant inactivating c-KIT catalytic domain mutations in distinct clinical forms of human mastocytosis. Proc Natl Acad Sci USA 96 (1999) 1609-1614
49. Hongyo T., Li T., Syaifudin M., et al. Specific c-kit mutations in sinonasal natural killer/T-cell lymphoma in China and Japan. Cancer Res 60 (2000) 2345-2347
50. Tian Q., Frierson Jr. H.F., Krystal G.W., et al. Activating c-kit gene mutations in human germ cell tumors. Am J Pathol 154 (1999) 1643-1647
51. Przygodzki R.M., Hubbs A.E., Zhao F.-Q., et al. Primary mediastinal seminomas: evidence of single and multiple KIT mutations. Lab Invest 82 (2002) 1369-1375
52. Kemmer K., Corless C.L., Fletcher J.A., et al. KIT mutations are common in testicular seminomas. Am J Pathol 164 (2004) 305-313
53. Hartmann K., Wardelmann E., Ma Y., et al. Novel germline mutation of KIT associated with familial gastrointestinal stromal tumors and mastocytosis. Gastroenterology 129 (2005) 1042-1046
54. Lasota J., Jasinski M., Sarlomo-Rikala M., et al. Mutations in exon 11 of c-kit occur preferentially in malignant versus benign gastrointestinal stromal tumors and do not occur in leiomyomas or leiomyosarcomas. Am J Pathol 154 (1999) 53-60
55. Taniguchi M., Nishida T., Hirota S., et al. Effect of c-kit mutation on prognosis of gastrointestinal stromal tumors. Cancer Res 59 (1999) 4297-4300
56. Sakurai S., Oguni S., Hironaka M., et al. Mutations in c-kit gene exons 9 and 13 in gastrointestinal stromal tumors among Japanese. Jpn J Cancer Res 92 (2001) 494-498
57. Andersson J., Sjogren H., Meis-Kindblom J.M., et al. The complexity of KIT gene mutations and chromosome rearrangements and their clinical correlation in gastrointestinal stromal (pacemaker cell) tumors. Am J Pathol 160 (2002) 15-22
58. Lee J.H., Zhang X., Jung W.Y., et al. DNA ploidy and c-KIT mutation in gastrointestinal stromal tumors. World J Gastroenterol 10 (2004) 3475-3479
59. Emile J.F., Theou N., Tabone S., et al. Clinicopathologic, phenotypic, and genotypic characteristics of gastrointestinal mesenchymal tumors. Clin Gastroenterol Hepatol 2 (2004) 597-605
60. Sakurai S., Fukasawa T., Chong J.M., et al. C-kit gene abnormalities in gastrointestinal stromal tumors (tumors of interstitial cells of Cajal). Jpn J Cancer Res 90 (1999) 1321-1328
61. Martin J., Poveda J., Llombart-Bosch A., et al. Deletions affecting codons 557-558 of the c-KIT gene indicate a poor prognosis in patients with completely resected gastrointestinal stromal tumors: a study by the Spanish Group for Sarcoma Research (GEIS). J Clin Oncol 23 (2005) 6190-6198
62. Williams C., Ponten F., Moberg C., et al. A high frequency of sequence alterations is due to formalin fixation of archival specimens. Am J Pathol 155 (1999) 1467-1471
63. Vu H.A., Xinh P.T., Kikushima M., et al. A recurrent duodenal gastrointestinal stromal tumor with a frameshift mutation resulting in a stop codon in KIT exon 13. Genes Chromosomes Cancer 42 (2005) 179-183
64. Corless C.L., McGreevey L., Haley A., et al. KIT mutations are common in incidental gastrointestinal stromal tumors one centimeter or less in size. Am J Pathol 160 (2002) 1567-1572
65. Cho S., Kitadai Y., Yoshida S., et al. Deletion of the KIT gene is associated with liver metastasis and poor prognosis in patients with gastrointestinal stromal tumor in the stomach. Int J Cancer 28 (2006) 1361-1367
66. Debiec-Rychter M., Cools J., Dumez H., et al. Mechanisms of resistence to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants. Gastroentereology 128 (2005) 270-279
67. Kikuchi, Yamashita K., Kawabata T., et al. Immunohistochemical and genetic features of gastric and metastatic liver gastrointestinal stromal tumors: sequential analyses. Cancer Sci 97 (2006) 127-132
68. Crosier P.S., Ricciardi S.T., Hall L.R., et al. Expression of isoforms of the human receptor tyrosine kinase c-kit in leukemic cell lines and acute myeloid leukemia. Blood 82 (1993) 1151-1158
69. Zhu W.M., Dong W.F., and Minden M. Alternative splicing creates two forms of the human kit protein. Leuk Lymphoma 12 (1994) 441-447
70. 715 deletion in GISTs mRNA is not detectable in genomic DNA and represents a previously known splice variant of KIT transcript. Am J Pathol 161 (2002) 739-741
71. Lasota J., Kopczynski J., Sarlomo-Rikala M., et al. KIT 1530ins6 mutation defines a subset of predominantly malignant gastrointestinal stromal tumors of intestinal origin. Human Pathol 34 (2003) 1306-1312
72. Heinrich M.C., Corless C.L., Demetri G.D., et al. Kinase mutations in imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 21 (2003) 4342-4349
73. Hostein I., Longy M., Gastaldello B., et al. Detection of a new mutation in KIT exon 9 in a gastrointestinal stromal tumor. Int J Cancer 118 (2006) 2089-2091
74. Antonescu C.R., Sommer G., Sarran L., et al. Association of KIT exon 9 mutation with nongastric primary site and aggressive behavior: KIT mutation analysis and clinical correlates of 120 gastrointestinal stromal tumors. Clin Cancer Res 9 (2003) 3329-3337
75. Hirota S., Nishida T., Isozaki K., et al. Gain-of-function mutation at the extracellular domain of KIT in gastrointestinal stromal tumours. J Pathol 193 (2001) 505-510
76. Wardelmann E., Hrychyk A., Markelbach-Bruse S., et al. Association of platelet-derived growth factor receptor α mutations with gastric primary site and epithelioid or mixed cell morphology in gastrointestinal stromal tumors. J Mol Diagn 6 (2004) 197-204
77. Subramanian S., West R., Corless C.L., et al. Gastrointestinal stromal tumors (GISTs) wit KIT and PDGFRA mutations have distinct gene expression profiles. Oncogene 23 (2004) 7780-7790
78. Wasag B., Debiec-Rychter M., Pauwels P., et al. Differential expression of KIT/PDGFRA mutant isoforms in epithelioid and mixed variants of gastrointestinal stromal tumors depends predominantly on the tumor site. Mod Pathol 17 (2004) 889-894
79. Koay M.H.E., Goh Y.-W., Iacopetta B., et al. Gastrointestinal stromal tuomours (GISTs): a clinicopathological and molecular study of 66 cases. Pathology 37 (2005) 22-31
80. Tornillo L., Duchini G., Carafa V., et al. Patterns of gene amplification in gastrointestinal stromal tumors (GIST). Lab Invest 85 (2005) 921-931
81. Andersson J., Bumming P., Meis-Kindblom J.M., et al. Gastrointestinal stromal tumors with KIT exon 11 deletions are associated with poor prognosis. Gastroenterology 130 (2006) 1573-1581
82. Yamamoto H., Oda Y., Kawaguchi K., et al. c-kit and PDGFRA mutations in extragastrointestinal stromal tumor (gastrointestinal stromal tumor of the soft tissue). Am J Surg Pathol 28 (2004) 479-488
83. Kim T.W., Lee H., Kang Y.-K., et al. Prognostic significance of c-kit mutation in localized gastrointestinal stromal tumors. Clin Cancer Res 10 (2004) 3076-3081
84. Kang H.J., Nam S.W., Kim H., et al. Correlation of KIT and platelet-derived growth factor receptor α mutations with gene activation and expression profiles in gastrointestinal stromal tumors. Oncogene 24 (2005) 1066-1074
85. Wardelmann E., Neidt I., Bierhoff E., et al. c-kit mutations in gastrointestinal stromal tumors occur preferentially in the spindle rather than in the epithelioid cell variant. Mod Pathol 15 (2002) 125-136
86. Corless C.L., McGreevey L., Town A., et al. KIT gene deletion at the intron 10-exon 11boundry in GI stromal tumors. J Mol Diag 6 (2004) 366-370
87. Chen L.L., Sabripour M., Wu E.F., et al. A mutation-created novel intra-exonic pre-mRNA splice site causes constitutive activation of KIT in human gastrointestinal stromal tumors. Oncogene 24 (2005) 4271-4280
88. Bumming P., Andersson J., Meis-Kindblom J.M., et al. Neoadjuvant, adjuvant and palliative treatment of gastrointestinal stromal tumours (GIST) with imatinib: a centre-based study of 17 patients. Cancer Res UK 89 (2003) 460-464
89. Chen L.L., Trent J.C., Wu E.F., et al. A missense mutation in KIT domain 1 correlates with imatinib resistance in gastrointestinal stromal tumors. Cancer Res 64 (2004) 5913-5919
90. Ernst S.I., Hubbs A.E., Przygodzki R.M., et al. KIT mutation portends poor prognosis in gastrointestinal stromal/smooth muscle tumors. Lab Invest 78 (1998) 1633-1636
91. Li Q.S., O'Leary T.J., Sobin L.H., et al. Analysis of KIT mutation and protein expression in fine needle aspirates of gastrointestinal stromal/smooth muscle tumors. Acta Cytol 44 (2000) 981-986
92. Morey A.L., Wanigesekera D., Hawkins N.J., et al. c-kit mutations in gastrointestinal stromal tumours. Pathology 34 (2002) 315-319
93. Theou N., Gil S., Devocelle A., et al. Multidrug resistance proteins in gastrointestinal stromal tumors: site-dependent expression and initial response to imatinib. Clin Cancer Res 11 (2005) 7593-7598
94. Frost D.F., Lasota J., and Miettinen M. Gastrointestinal stromal tumors and leiomyomas in the dog-a clinicopathologic, immunohistochemical molecular genetic study of 50 cases. Vet Pathol 61 (2003) 42-54
95. Went P., Dirnhofer S., Bundi M., et al. Prevalence of KIT expression in human tumors. J Clin Oncol 22 (2004) 4514-4522
96. Willmore-Payne C., Holden J.A., Hirschowitz S., et al. BRAF and c-kit gene copy number in mutation positive malignant melanoma. Hum Pathol 37 (2006) 520-527
97. Choi Y.R., Kim H., Kang H.J., et al. Overexpression of high mobility group box 1 in gastrointestinal stromal tumors wit KIT mutation. Cancer Res 63 (2003) 2188-2193
98. Moskaluk C.A., Tian Q., Marshall C.R., et al. Mutations of c-kit JM domain are found in a minority of human gastrointestinal stromal tumors. Oncogene 18 (1999) 1897-1902
99. Feng F., Liu X.H., Xie Q., et al. Expression and mutation of c-kit gene in gastrointestinal stromal tumors. Worl J Gastroenterol 9 (2003) 2548-2551
100. Hou Y.Y., Tan Y.S., Sun M.H., et al. C-kit gene mutation in gastrointestinal stromal tumors. Worl J Gastroenterol 10 (2004) 1310-1314
101. Lasota J., Dansonka-Mieszkowska A., Stachura T., et al. Gastrointestinal stromal tumors with internal tandem duplications in 3′ end of KIT juxtamembrane domain occur predominantly in stomach and generally seem to have a favorable course. Mod Pathol 16 (2003) 1257-1264
102. Corbacioglu S., Kilic M., Westhoff M.A., et al. Newly identified c-kit receptor tyrosine kinase ITD in childhood AML induces ligand independent growth and is responsive to a synergistic effect of imatinib and rapamycin. Blood (2006) E-pub 1-26, July 13
103. Yokota S., Kiyoi H., Nakao M., et al. Internal tandem duplication of the FLT3 gene is preferentially seen in acute myeloid leukemia and myelodysplastic syndrome among various hematological malignancies: a study on a large series of patients and cell lines. Leukemia 11 (1997) 1605-1609
104. Zwaan C.M., Meshinchi S., Radich J.P., et al. FLT3 internal tandem duplication in 234 children with acute myeloid leukemia: prognostic significance and relation to cellulare drug resistance. Blood 102 (2003) 2387-2394
105. Miettinen M., Monihan J.M., Sarlomo-Rikala M., et al. Gastrointestinal stromal tumors/smooth muscle tumors/GISTs in the omentum and mesentery: clinicopathologic and immunohistochemical study of 26 cases. Am J Surg Pathol 23 (1999) 1109-1118
106. Miettinen M., Sarlomo-Rikala M., Sobin L.H., et al. Esophageal stromal tumors: a clinicopathologic, immunohistochemical, and molecular genetic study of 17 cases and comparison with esophageal leiomyomas and leiomyosarcomas. Am J Surg Pathol 24 (2000) 211-222
107. Miettinen M., Sarlomo-Rikala M., Sobin L.H., et al. Gastrointestinal stromal tumors and leiomyosarcomas in the colon: a clinicopathologic, immunohistochemical and molecular genetic study of 44 cases. Am J Surg Pathol 24 (2000) 1339-1352
108. Miettinen M., Furlong M., Sarlomo-Rikala M., et al. Gastrointestinal stromal tumors, intramural leiomyomas, and leiomyosarcomas in the rectum and anus. A clinicopathologic, immunohistochemical and molecular genetic study of 144 cases. Am J Surg Pathol 25 (2001) 1121-1133
109. Miettinen M., and Sobin L.H. Gastrointestinal stromal tumors in the appendix: a clinicopathologic and immunohistochemical study of four cases. Am J Surg Pathol 25 (2001) 1433-1437
110. Miettinen M., Kopczynski J., Maklouf H.R., et al. Gastrointestinal stromal tumors, intramural leiomyomas and leiomyosarcomas in the duodenum: a clinicopathologic, immunohistochemical and molecular genetic study of 167 cases. Am J Surg Pathol 27 (2003) 625-641
111. Miettinen M., Sobin L.H., and Lasota J. Gastrointestinal stromal tumors (GISTs) of the stomach: a clinicopathologic, immunohistochemical and molecular genetic study of 1756 cases with long-term follow-up. Am J Surg Pathol 29 (2005) 52-68
112. Miettinen M., Makhlouf H., Sobin L.H., et al. Gastrointestinal stromal tumors (GISTs) of the jejunum and ileum: a clinicopathologic, immunohistochemical and molecular genetic study of 906 cases before imatinib with long-term follow-up. Am J Surg Pathol 30 (2006) 477-489
113. Haller F., Gunawan B., von Heydebreck A., et al. Prognostic role of E2F1 and members of the CDKN2A network in gastrointestinal stromal tumors. Clin Cancer Res 11 (2005) 6589-6597
114. He H.Y., Xiang Y.N., Zhong H.H., et al. c-kit and PDGFRS mutations in 60 cases of gastrointestinal tumors (GISTs). Beijing Da Xue Xue Bao 37 (2005) 320-324
115. Che S., Kitadai Y., Yoshida S., et al. Deletion of the KIT gene is associated with liver metastasis and poor prognosis in patients with gastrointestinal stromal tumor in the stomach. Int J Oncol 28 (2006) 1361-1367
116. Medeiros F., Corless C.L., Duensing A., et al. KIT-negative gastrointestinal stromal tumors. Proof of concept and therapeutic implications. Am J Surg Pathol 28 (2004) 889-894
117. Hirota S., Ohashi A., Nishida T., et al. Gain-of-function mutations of platelet-derived growth factor receptor α gene in gastrointestinal stromal tumors. Gastroenterology 125 (2003) 660-667
118. Kinoshita K., Hirota S., Isozaki K., et al. Absence of c-kit gene mutations in gastrointestinal stromal tumours from neurofibromatosis type 1 patients. J Pathol 202 (2004) 80-85
119. Andersson J., Sihto H., Meis-Kindblom J.M., et al. NF1-associated gastrointestinal stromal tumors have unique clinical, phenotypic, and genotypic characteristics. Am J Surg Pathol 29 (2005) 1170-1176
120. Takazawa Y., Sakurai S., Sakuma Y., et al. Gastrointestinal stromal tumors of neurofibromatosis type I (von Recklinghausen's disease). Am J Surg Pathol 29 (2005) 755-763
121. Yantiss R., Rosenberg A.E., Sarran L., et al. Multiple gastrointestinal stromal tumors in type I neurofibromatosis: a pathologic and molecular study. Modern Pathol 18 (2005) 475-484
122. Bumming P., Nilsson B., Sorensen J., et al. Use of 2-tracer PET to diagnose gastrointestinal stromal tumour and pheochromocytoma in patients with Carney triad and neurofibromatosis type 1. Scand J Gastroenterol 41 (2005) 626-630
123. Miettinen M., Fetsch J.F., Sobin L.H., et al. Gastrointestinal stromal tumors in patients with neurofibromatosis 1: a clinicopathologic and molecular genetic study of 45 cases. Am J Surg Pathol 30 (2006) 90-96
124. Nemoto H., Tate G., Schirinzi A., et al. Novel NF1 gene mutation in a Japanese patient with neurofibromatosis type 1 and a gastrointestinal stromal tumor. J Gastroenterol 41 (2006) 378-382
125. Miettinen M., Lasota J., and Sobin L.H. Gastrointestinal stromal tumors of the stomach in children and young adults. Am J Surg Pathol 29 (2005) 1-9
126. Prakash S., Sarran L., Socci N., et al. Gastrointestinal stromal tumors in children and young adults: a clinicopathologic, molecular, and genomic study of 15 cases and review of the literature. J Pediatr Hematol Oncol 27 (2005) 179-187
127. O'Sullivan M.J., McCabe A., Gillett P., et al. Multiple gastric stromal tumors in a child without syndromic association lacks common KIT or PDGFRalpha mutations. Pediatr Dev Pathol 8 (2005) 685-689
128. Kuroiwa M., Hiwatari M., Hirato J., et al. Advanced-stage gastrointestinal stromal tumor treated with imatinib in a 12-year-old girl with unique mutation of PDGFRA. J Pediatr Surg 40 (2005) 1798-1801
129. Price V.E., Zielenska M., Chilton-MacNeill S., et al. Clinical and molecular characteristics of pediatric gastrointestinal stromal tumors (GISTs). Pediatr Blood Cancer 45 (2005) 20-24
130. Diment J., Tamborini E., Casali P., et al. Carney triad: case report and molecular analysis of gastric tumor. Hum Pathol 36 (2005) 112-116
131. Perry C.G., Young Jr. W.F., McWhinney S.R., et al. Functioning paraganglioma and gastrointestinal stromal tumor of the jejunum in three women: syndrome or coincidence. Am J Surg Pathol 30 (2006) 42-49
132. Wardelmann E., Losen I., Hans V., et al. Deletion of Trp-557 and Lys-558 in the juxtamembrane domain of the c-kit protooncogene is associated with metastatic behavior of gastrointestinal stromal tumors. Int J Cancer 106 (2003) 887-895
133. Kinoshita K., Isozaki K., Hirota S., et al. c-kit gene mutation at exon 17 and 13 is very rare in sporadic gastrointestinal stromal tumors. J Gastroenterol Hepatol 18 (2003) 147-151
134. Pauls K., Merkelbach-Bruse S., Buttner R., et al. PDGFRα and c-kit-mutated gastrointestinal stromal tumours (GISTs) are characterized by distinctive histological and immunohistochemical features. Histopathology 46 (2005) 166-175
135. van Oosterom A.T., Judson I., Verweij J., et al. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet 358 (2001) 1421-1423
136. Demetri G.D., von Mehren M., Blanke C.D., et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347 (2002) 472-480
137. Faivre S., Delbaldo C., Vera K., et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 24 (2006) 25-35
138. Prenen H., Cools J., Mentens N., et al. Efficacy of the kinase inhibitor SU11248 against gastrointestinal stromal tumor mutants refractory to imatinib mesylate. Clin Cancer Res 12 (2006) 2622-2627
139. Van Glabbeke M., Verweij J., Casali P.G., et al. Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: a European Organization for Research and Treatment of Cancer-Italien Sarcoma Group-Australasian Gastrointestinal Trials Group study. J Clin Oncol 23 (2005) 5795-5804
140. Corless C.L., Fletcher J.A., and Heinrich M.C. Biology of gastrointestinal stromal tumors. J Clin Oncol 22 (2004) 3813-3825
141. Debiec-Rychter M., Sciot R., Le Cesne A., et al. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumors. Eur J Cancer 42 (2006) 1093-1103
142. Chen L.L., Sabripour M., Andtbacka R.H.I., et al. Imatinib resistance in gastrointestinal stromla tumors. Curr Oncol Rep 7 (2005) 293-299
143. Tamborini E., Bonadiman L., Greco A., et al. A new mutation in the KIT ATP pocket causes acquired resistance to imatinib in a gastrointestinal stromal tumor patient. Gastroenterology 127 (2004) 294-299
144. Antonescu C.R., Besmer P., Guo T., et al. Acquired resistance to imatinib in gastrointestinal stromal tumors occurs through secondary gene mutation. Clin Cancer Res 11 (2005) 4182-4190
145. 654Ala. Mol Cancer Ther 4 (2005) 2008-2015
146. Wardelmann E., Thomas N., Merkelbach-Bruse S., et al. Acquired resistance to imatinib in gastrointestinal stromal tumours caused by multiple KIT mutations. Lancet Oncol 6 (2005) 249-251
147. Wardelmann E., Merkelbach-Bruse S., Pauls K., et al. Polyclonal evolution of multiple secondary KIT mutations in gastrointestinal stromal tumors under treatment with imatinib mesylate. Clin Cancer Res 12 (2006) 1743-1749